Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited, to speak at Jefferies 2019 London Healthcare Conference
LONDON (United Kingdom) – November 19, 2019 – Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited, to speak at Jefferies...
Telix Pharmaceuticals Program Update Q3 2019
MELBOURNE (Australia) – Nov. 4, 2019 - Telix Pharmaceuticals Ltd Program Update Q3, 2019
Telix Pharmaceuticals to Acquire European Production Facility
MELBOURNE (Australia) and BRUSSELS (Belgium) – Oct. 3, 2019 - Telix Pharmaceuticals Ltd is pleased to announce that it has...
Telix Cleared to Commence Renal Cancer Imaging Study in Japan
Melbourne (Australia) and Kyoto (Japan) – 30 August 2019. Telix Pharmaceuticals Limited today announced the completion of a Clinical Trial...